Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (October 2022)
39 slides from Genprex's investor presentation, Oct 11, 2022
Slide 1: Pioneering Gene Therapies for Large Patient Populations
©) Genprex PIONEERING GENE THERAPIES FOR LARGE PATIENT POPULATIONS NASDAQ: GNPX October 2022
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements contained inthis presentation regarding matters that are not historical facts are "forward ooking statements" within the meaning of the Private Secures Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS MAJOR COMPETITIVE ADVANTAGES + GENE THERAPY PLATFORM TWO LUNG CANCER CLINICAL TRIALS CURRENTLY ENROLLING FIRST SYSTEMIC GENE THERAPY USED FOR CANCER IN HUMANS. > 4 NOVEL GENE THERAPY PROGRAM IN DIABETES LARGE MARKETS AND UNMET NEED | + WORLD-CLASS ACADEMIC PARTNERS TWO FDA FAST
Slide 4: Advancing Gene Therapy in Large Indications
ADVANCING GENE THERAPY IN LARGE INDICATIONS HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES REQORSA™ is the first systemic gene therapy in development for cancer. Initially targeting solid tumors in lung cancers. Clinical trials include combinations of REQORSA with AstraZeneca’s to
Slide 5: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE ‘oncoLocy GOR WORROGE TGA VLE O00 _E— reqonsitnmunocene werary —yscic_—oN 02" —_| ESSE reqorsimnmenocereTierry nace =A ESS a REQORSA™ MaUNOGENE THERAPY nscuc Accicin-2 (ESTA aaa REQORSA™ IMMUNOGENE THERAPY sac — wnossciose vanousoncotosy rancers > DUABETES ort macs
Slide 6: Oncology Program
ONCOLOGY PROGRAM REPROGRAMMING THE COURSE OF CANCER
Slide 7: Lead Program: Non-Small Cell Lung Cancer
LEAD PROGRAM: NON-SMALL CELL LUNG CANCER RECENT EXPANSION TO SCLC COVERS VIRTUALLY ENTIRE MARKET 4% S5B+ MOST COMMON LUNG CANCER TAGRISSO 2021 SALES NSCLC represents the majority of all lung cancers’. AstraZeneca’s highest grossing product. WORLDWIDE LUNG CANCER CASES KEYTRUDA 2021 SALES More than t
Slide 8: Tumor Suppressor Genes Deleted During Cancer Development
TUMOR SUPPRESSOR GENES DELETED DURING CANCER DEVELOPMENT Tumor suppressor genes such as TUSC2 are deleted early during cancer development 80% of all non-small cell lung cancers express decreased amounts of TUSC2 tumor suppressor protein Loss or reduction of TUSC2 expression is associated with signif
Slide 9: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM The first systemic gene therapy delivery platform for cancer GENES SYNERGIES Multiple tumor Advanced approach suppressor genes using combination therapy CANCERS Multiple cancers Genprex Nasdaq: GNPX
Slide 10: Oncoprex Nanoparticle Delivery System
ONCOPREX® NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS Tusc2 containing YA 8"* REQORSA™ IMMUNOGENE THERAPY, Next gen non-viral, positively-charged lipid nanoparticle (LNP) is systemically delivered ) Genprex Nasdag: GNPX 10
Slide 11: Selective Uptake of REQORSA
SELECTIVE UPTAKE OF REQORSA™ PATIENT 1 (0.02 mg/kg) PATIENT 2 (0.06 ma/ka) PRE-TREATMENT BIOPSIES In all images, blue stain shows cell nuclei and red stain shows TUSC2 protein POST-TREATMENT BIOPSIES Selective and Preerentil Cancer Cell Uta and AntCancer tty in Advanced Lung Cancer Patients. Lust a
Slide 12: REQORSA Targets Cancer at Its Core
REQORSA TARGETS CANCER AT ITS CORE MULTIPLE ANTI-CANCER MECHANISMS OF ACTION CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS = MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Genprex Nasdaecwex
Slide 13: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Highest dose used
Slide 14: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE 2 DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS PATIENT EGFR STATUS RESPONSE PRIOR THERAPY ue ee Ge Positive (exon 18120) Complete Response Chemo Negative 2496 regression Target Lesion Chemo / anti-PD1 2 30% regression one Target Lesion Negative’ 18% regression
Slide 15: AACR 21: REQORSA + Tagrisso Reduce Tumor Growth in Tagrisso-Resistant Tumors
AACR 21: REQORSA + TAGRISSO REDUCE TUMOR GROWTH IN TAGRISSO-RESISTANT TUMORS ‘Osimertinib+TUSC2 combination on H1975-OsiR tumors in NSG mice Osimertinib+TUSC2 combination on H1975 tumors in NSG mice ‘Osimertinib isthe generic name for Tagrisso. REQORSA referred to as TUSC2 in figures. Nasdaq: enex 1
Slide 16: Acclaim-1 Study Characteristics
ste GENERAL STUDY CHARACTERISTICS i ° + FDA Fast Track Designation 2° Patients with advanced, EGFR mutant NSCLC whose disease ay ee Acclaim - 1 + ~15US, sites baal eT paiiants = Cohen Compas REQORSA in combination with AstraZeneca's Tagrisso for NSCLC Phase 2: 74 patients Interim analysis at 25 even
Slide 17: Acclaim-1 Study Design
PHASE 1 PHASE 2 COMPONENT ie a 6 a = fe) STUDY DESIGN 3+3 dose escalation of REQORSA in combination with Tagrisso STUDY DESIGN Randomized 1:1, open- label, 2-arm study of REQORSA in. combination with Tagrisso vs. Tagrisso monotherapy PRIMARY ENDPOINT Dose limiting toxicity PRIMARY ENDPOINT Progressi
Slide 18: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER Survival on Lung Metastasis Model tusca-Treated 104 = powers : . = Eta 70 18 20 a6 Daye ” +6 . TUSC2+anti-PD1 combination significantly prolonged TUSC2+anti-PD1 exhibit greater a
Slide 19: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda ‘The independent immunologic effects of REQORSA and Keytruda create synergy by adding increased immunologic attack on the tumor to PD-1 inhibition, REQORSA referred t
Slide 20: AACR 21: REQORSA May Enhance First-Line Standard of Care
AACR 21: REQORSA MAY ENHANCE FIRST-LINE STANDARD OF CARE REQORSA + Keytruda + Chemo + REQORSA enhances the efficacy of chemo-immunotherapy on KL-mutant lung metastases in humanized mice. + Triple combination demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (K
Slide 21: Acclaim-2 Study Characteristics
PHASE 1 GENERAL STUDY CHARACTERISTICS FDA Fast Track Designation (received December 2021) Patients with advanced NSCLC whose disease progressed after treatment with Keytruda ~10 US. sites ~156 patients Phase 1: Up to 30 patients Phase 2: 126 patients Interim analysis at 50 events (ie., disease progr
Slide 22: Acclaim-2 Study Design
ail Acclaim -2 STUDY DESIGN PRIMARY ENDPOINT + 3+3 dose escalation of + Dose limiting toxicity REQORSA in combination with Keytruda PHASE 1 COMPONENT 5 STUDY DESIGN PRIMARY ENDPOINT SECONDARY ENDPOINTS ag Randomized 2:1,open- «Progression free survival (PFS) «Overall response rate wz label, 2-arm st
Slide 23: REQORSA in Small Cell Lung Cancer
REQORSA IN SMALL CELL LUNG CANCER Targeting Small Cell Lung Cancer (in addition to NSCLC) allows Genprex to address virtually the entire lung cancer market. ‘Small Cell Lung Cancer: + Consistently has low TUSC2 protein levels + Documented to often have deletion of one TUSC2 geneallele + Extensive st
Slide 24: Scaled-Up Clinical Grade Manufacturing
SCALED-UP CLINICAL GRADE MANUFACTURING POSITIONS COMPANY FOR SUCCESS IN LUNG CANCER THERAPEUTICS MARKET FOCUS ON Achievement highlighted by important process improvements and significantly improved economies of scale. LEAD WITH Successful completion of technology transfer INNOVATION and scale-up of
Slide 25: oYV
ie Es Ww oYV <2 Oa
Slide 26: Diabetes Program
Genprex DIABETES PROGRAM COLLABORATION WITH UNIVERSITY OF PITTSBURGH TO TREAT DIABETES 37.3M or 11.3% of Americans Have Diabetes" Type 1 Diabetes: An auto-immune condition where the body's immune system destroys pancreatic beta cells that make insulin. Generally occurs in children and adolescents. T
Slide 27: Diabetes: A Global Epidemic
DIABETES: A GLOBAL EPIDEMIC 537M S966B DIABETES PREVELANCE ~ GLOBAL? EST ANNUAL GLOBAL DIABETES EXPENDITURES Expected to rise to 643M by 2030 and 783M by 2045. 316% increase in global healthcare expenditures since 20062, ‘S415B expenditures (43%) associated w/ US and Caribbean. 37.3M 24B DIABETES PR
Slide 28: The Long-Term Damage of Diabetes
THE LONG-TERM DAMAGE OF DIABETES HEART DISEASE Leading cause of death for men and women in U.S. Diabetics are 2x as likely to have heart disease or a stroke. CHRONIC KIDNEY DISEASE (CKD) Approximately 1 in 3 adults with diabetes have CKD. Kidney diseases are the St* leading cause of death in U.S, NE
Slide 29: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION 8 Novel infusion process uses an endoscope and an Htme* or AAV vector to deliver the Pdx1 + MafA genes to the Wypereemis By pancreas. » Intraductal infusion F of Pic and Mofo" In T10, it transforms alpha cells in the pancrea
Slide 30: Corporate
Slide 31: Meet Our Team: Company Management
Genprex MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman, President & Chief Executive Officer + 30+ years of expertise in corporate law, including corporate governance, in blotech industry + Former owner of securities broker dealer firm RYAN CONFER, MS Chief Financial Officer + 10+ years
Slide 32: Meet Our Team: Company Management
Genprex MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD Senior Vice President, Intellectual Property and Licensing 20+ years of expertise in biotech IP law, business ‘development, licensing transactions + Seasoned IP executive and attorney DAVID SCHLOSS, JD Senior Vice President, Human Resourc
Slide 33: Meet Our Team: Scientific Advisory Board
Genprex MEET OUR TEAM SCIENTIFIC ADVISORY BOARD JACK A. ROTH MD, FACS, Chairman + Professor and Bud Johnson Distinguished Clinical Chair, Department of Thoracic and Cardiovascular Surgery; Chief, Section of Thoracic Molecular Oncology; Professor of Molecular and Cellular ‘Oncology; UT MO Anderson Di
Slide 34: Meet Our Team: Clinical Advisory Board
MEET OUR TEAM CLINICAL ADVISORY BOARD COL. GEORGE PEOPLES MD, FACS MICHAEL MORSE MD, MHS, FACP. + Professor of Medicine, Division of Medical Oncology inthe Department of Surgery at Ouke University boutique cancer immunotherapy CRC + Research expertise in targeted therapies and * Professor of Surgery
Slide 35: Meet Our Team: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board + 30+ years of expertise in corporate law, including corporate governance, in biotech industry Former owner of securities broker dealer firm JOSE A. MORENO TOSCANO Board Director + Chief Executive Officer, LFB USA In + 30s year
Slide 36: GNPX at a Glance
GNPX AT A GLANCE F . x weence: |e 5 aRRERC 30-DAY AVG SHARES GS COMPANY SYMBOL EXCHANGE SHARE PRICE | MARKET CAP RO AN Coe eae CASH Genprex. Inc. GNPX Nasdaq S137 65M 96K 47,878,351 ‘$30 Million All data are as of October 7, 2022, except for shares outstanding and cash which ore os of June 30, 2022.
Slide 37: Achievements and Upcoming Milestones
ACHIEVEMENTS AND UPCOMING MILESTONES RECENT ACHIEVEMENTS Dose the first patient in Acclaim-2 Approval from Safety Review Committee to advance Acclaim-1 to higher dosing in second cohort of Phase 1 portion of study Expand indications to small cell lung cancer (expand on sponsored research) Sponsored
Slide 38: We Believe 21st Century Gene Therapies
WE BELIEVE 21ST CENTURY GENE THERAPIES LARGE MARKETS AND UNMET NEED IN A FUTURE OF COMBINATION TRIALS WITH TOP TRANSFORMATIONAL SELLING DRUGS TWO FDA FAST TRACK DESIGNATIONS PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS. Nasdag: GNPX 38
Slide 39: Genprex
oO Genprex’ NASDAQ: GNPX (877) 774-GNPX | investors@genprex.com Nasdaq: GNPX